

**LEMAITRE VASCULAR, INC (NASDAQ: LMAT)****NON-GAAP FINANCIAL MEASURES**

(amounts in thousands)

(unaudited)

## Reconciliation between GAAP and Non-GAAP XenoSure sales growth:

For the three months ended March 31, 2019

XenoSure sales as reported	\$ 5,755	
Impact of currency exchange rate fluctuations	<u>186</u>	
Adjusted sales for the three months ended March 31, 2019		\$ 5,941

For the three months ended March 31, 2018

XenoSure sales as reported		\$ 5,860	
Adjusted XenoSure sales increase for the three months ended March 31, 2019		<u>\$ 81</u>	<u>1%</u>

## Reconciliation between GAAP and Non-GAAP valvulotome sales growth:

For the three months ended March 31, 2019

Valvulotome sales as reported	\$ 5,414	
Impact of currency exchange rate fluctuations	179	
Impact of acquisitions excluding currency	<u>(154)</u>	
Adjusted sales for the three months ended March 31, 2019		\$ 5,439

For the three months ended March 31, 2018

Valvulotome sales as reported		\$ 5,286	
Adjusted Valvulotome sales increase for the three months ended March 31, 2019		<u>\$ 153</u>	<u>3%</u>